Next-generation sequencing refers to the deep, high-throughput, in-parallel DNA sequencing technologies developed a couple of decades after the Sanger DNA sequencing method first emerged in 1977. It is a massively parallel sequencing technology that offers scalability, ultra-high throughput, and high speed to determine the order of nucleotides in the entire genome. DNA pre-sequencing is one of the most significant steps in the overall sequencing protocol as it involves the preparation of the sample for the subsequent sequencing reaction. Further, the expansion of the worldwide next-generation sequencing market is majorly driven by a rise in genome mapping programs, a rise in applications of next-generation sequencing; an increase in healthcare expenditure; and technological advancements in sequencing platforms. According to Renub Research, The Next Generation Sequencing Market will reach US$ 34.8 Billion by 2027.
Impact of COVID-19 Pandemic
The potential advantage of NGS diagnostic technology was to determining the genetic sequence of a virus and helping scientists understand the change of the virus. Throughout the COVID-19 pandemic, government authorities worldwide are constantly working with the private sector to bring NGS technology the potential diagnostic tool within the market. In 2020, the (US FDA) United States Food and Drug Administration issued an emergency use authorized (EUA) to Illumina Inc. for the first COVID-19 diagnostic test adopting NGS technology. The FDA approved the Illumina COVID Seq Test for the qualitative detection of SARS-CoV-2 RNA.
Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=next-generation-sequencing-market-p.php
Based on Type
Next Generation Sequencing Market includes Targeted Re-sequencing (TPS/WES), RNA-Sequencing, Whole Genome Sequencing, Chip-Sequencing, De Novo Sequencing, and Methyl-Sequencing. Targeted Re-sequencing holds the largest market share; the technology allows economic options for WGS (World Geodetic System) and facilitates the in-depth study of genomic regions. RNA-based targeted sequencing is expected to witness lucrative growth in the coming years due to the growing demand for differential expression analysis. As per this report, the Next-generation Sequencing Industry will grow with a CAGR of 22.94% by 2027.
Moreover, in recent years, NGS has been considered the most potent tool in diagnostics and research to understand the treatment regimen for various diseases, including cancer, infectious diseases and cardiovascular diseases. In cancer diagnostics, due to the widespread adoption of liquid biopsies, there has been a significant increase in the utilization of NGS technologies. These technologies utilize cell-free circulating tumour DNA (ctDNA) as a non-invasive cancer biomarker for real-time cancer monitoring and detection.
NGS is steadily being integrated into user verticals like Academic and Research Institutes, Biopharmaceutical Industry, Diagnostics Industry, Governments Agencies, Hospitals and Clinics. The academic and Biopharmaceutical Industry dominates the NGS industry. Academic created the most significant revenue to the high usage of the next-generation sequencing platforms for basic research programs within universities and institutes. As per this study, Next-generation sequencing Market Size was US$ 8.2 Billion in 2020.
In addition, Next-generation sequencing informatics Services are used in clinical applications of NGS, technological advancements in NGS informatics tools, growing preference toward personalized medicines and early disease diagnosis, and the increasing demand for NGS services and investments by key companies.
The key players include Illumina, Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore Technologies, and Roche. They were operating in the global next-generation sequencing market. In 2020, Illumina Inc. acquired GRAIL, a healthcare company focused on multi-cancer early detection, for cash and stock consideration of US$ 8 Billion upon closing of the transaction.
Renub Research latest report “Next-generation sequencing Market by Types of Test (Targeted Re-sequencing (TPS/WES), RNA-Sequencing, Whole Genome Sequencing, ChIP-Sequencing, De Novo Sequencing, and Methyl-Sequencing) by Disease (Reproductive Health NGS test , NGS Test Market (Rare Disease Diagnostics), Cancer (Risk Prediction, therapy Selection & Respose), Metabolic Immune (Diagnostic), Cardiovascular NGS Test Market, Others NGS Test Market) by Informatics (NGS Informatics Services, Primary and Secondary Data Analysis Tools, Computing, Storage, Biological Interpretation and Reporting Tools, LIMS (Laboratory Information Management System) by End User (Academic and Research Institutes, Biopharmaceutical Industry, Diagnostics Industry, Governments Agencies, Hospitals and Clinics)” provides a detailed analysis of Next-generation sequencing Industry.
Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/next-generation-sequencing-market-p.php
Types of Test – Next Generation Sequencing Market have been covered from 6 viewpoints:
1. Targeted Re-sequencing (TPS/WES)
2. RNA-Sequencing
3. Whole Genome Sequencing
4. ChIP-Sequencing
5. De Novo Sequencing
6. Methyl-Sequencing
Disease – Global Next Generation Sequencing Test Market have been covered from 6 viewpoints:
1. Reproductive Health NGS test
2. NGS Test Market (Rare Disease Diagnostics)
3. Cancer (Risk Prediction, therapy Selection & Response)
4. Metabolic Immune (Diagnostic)
5. Cardiovascular NGS Test Market
6. Others NGS Test Market
Informatics – Global Next Generation Sequencing Market have been covered from 6 viewpoints:
1. NGS Informatics Services
2. Primary and Secondary Data Analysis Tools
3. Storage
4. Computing
5. Biological Interpretation and Reporting Tools
6. LIMS (Laboratory Information Management System)
End User – Global Next Generation Sequencing Market have been covered from 5 viewpoints:
1. Academic and Research Institutes
2. Biopharmaceutical Industry
3. Diagnostics Industry
4. Governments Agencies
5. Hospitals and Clinics
Company Insights:
• Overview
• Company Initiatives
• Sales Analysis
Companies Covered:
1. Illumina
2. Thermo Fisher Scientific
3. Pacific Biosciences
4. Oxford Nanopore Technologies
5. Roche
Industry Related Reports:
Industrial Enzymes Market: https://www.renub.com/industrial-enzymes-market-p.php
China In-Vitro Fertilization Market: https://www.renub.com/china-in-vitro-fertilization-market-p.php
France In-Vitro Diagnostics (IVD) Market: https://www.renub.com/france-in-vitro-diagnostics-market-p.php
United States In Vitro Diagnostics Market: https://www.renub.com/united-state-in-vitro-diagnostics-market-p.php
Food Safety Testing Market: https://www.renub.com/food-safety-testing-market-p.php
Prostate Cancer Diagnostics Market: https://www.renub.com/prostate-cancer-diagnostics-market-p.php
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers, and executives to make informed and correct decisions.
Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today’s ultra-competitive markets.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research